Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Potential use of HMG-CoA reductase inhibitors for osteoporosis.

Cushenberry LM, de Bittner MR.

Ann Pharmacother. 2002 Apr;36(4):671-8. Review.

PMID:
11918519
2.

Hydroxymethylglutaryl-coenzyme A reductase inhibitors in osteoporosis management.

Coons JC.

Ann Pharmacother. 2002 Feb;36(2):326-30. Review.

PMID:
11847956
3.

HMG-CoA reductase inhibitors in osteoporosis: do they reduce the risk of fracture?

Schlienger RG, Meier CR.

Drugs Aging. 2003;20(5):321-36. Review.

PMID:
12696993
4.

Statins and osteoporosis: new role for old drugs.

Jadhav SB, Jain GK.

J Pharm Pharmacol. 2006 Jan;58(1):3-18. Review.

PMID:
16393459
5.

Skeletal effects of statins.

Yaturu S.

Endocr Pract. 2003 Jul-Aug;9(4):315-20. Review.

PMID:
14561578
6.

Atorvastatin in the treatment of primary hypercholesterolemia and mixed dyslipidemias.

Yee HS, Fong NT.

Ann Pharmacother. 1998 Oct;32(10):1030-43. Review.

PMID:
9793596
7.

Hydroxymethylglutaryl-coenzyme A reductase inhibitors and osteoporosis: a meta-analysis.

Hatzigeorgiou C, Jackson JL.

Osteoporos Int. 2005 Aug;16(8):990-8. Epub 2005 Mar 3. Review.

PMID:
15744453
8.
9.

Treatment of childhood hypercholesterolemia with HMG-CoA reductase inhibitors.

Duplaga BA.

Ann Pharmacother. 1999 Nov;33(11):1224-7. Review.

PMID:
10573325
10.

HMG CoA reductase inhibitors and the skeleton: a comprehensive review.

Bauer DC.

Osteoporos Int. 2003 Jun;14(4):273-82. Epub 2003 May 8. Review.

PMID:
12736772
11.

Statins and osteoporosis: a clinical review.

Gonyeau MJ.

Pharmacotherapy. 2005 Feb;25(2):228-43. Review.

PMID:
15767237
12.
13.
14.

3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy.

Tzefos M, Olin JL.

J Clin Lipidol. 2011 Nov-Dec;5(6):450-9. doi: 10.1016/j.jacl.2011.06.013. Epub 2011 Jun 28. Review.

PMID:
22108148
15.

[Statins as a new therapeutic possibility in osteoporosis? Wishful thinking as opposed to data].

Barthel HR.

Dtsch Med Wochenschr. 2001 Oct 19;126(42):1189-90. German. No abstract available.

PMID:
11607863
16.

Should we abandon statins in the prevention of bone fractures?

Esposito K, Capuano A, Sportiello L, Giustina A, Giugliano D.

Endocrine. 2013 Oct;44(2):326-33. doi: 10.1007/s12020-013-9924-z. Epub 2013 Mar 24. Review.

PMID:
23526261
17.

Efficacy of HMG-CoA reductase inhibitors in treating osteoporosis.

Richard AA, Harrison TM.

Am J Health Syst Pharm. 2002 Feb 15;59(4):372-7. Review.

PMID:
11885403
18.

Use of statins and fracture: results of 4 prospective studies and cumulative meta-analysis of observational studies and controlled trials.

Bauer DC, Mundy GR, Jamal SA, Black DM, Cauley JA, Ensrud KE, van der Klift M, Pols HA.

Arch Intern Med. 2004 Jan 26;164(2):146-52.

PMID:
14744837
19.

Alternate-day dosing of HMG-CoA reductase inhibitors for cholesterol reduction.

Metz CA, Lucas KH.

Ann Pharmacother. 2001 Apr;35(4):496-500. Review.

PMID:
11302415
20.

The potential role of HMG-CoA reductase inhibitors in pediatric nephrotic syndrome.

Prescott WA Jr, Streetman DA, Streetman DS.

Ann Pharmacother. 2004 Dec;38(12):2105-14. Epub 2004 Oct 26. Review.

PMID:
15507504

Supplemental Content

Support Center